Print
|
Close
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Active:
Yes
Cancer Type:
Lung Cancer
NCT ID:
NCT01630733
Trial Phases:
Phase III
Protocol IDs:
TV1011-LC-303 (primary)
2012-002447-14
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Achieve Life Sciences
NCI Full Details:
http://clinicaltrials.gov/show/NCT01630733
Summary
The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.